Yesterdays PR was terrific. Brilacidin was found t
Post# of 72447
(Total Views: 3016)
Posted On: 05/20/2020 8:55:40 PM
Yesterdays PR was terrific. Brilacidin was found to be virucidal which means it can kill viruses on contact. It also IMO confirms the viral mechanism of action of opening the viral coat or capsid. As Leo stated this property is unique and important as virtually all antiviral pharmaceuticals are virustatic which means they have to penetrate the viral coat and interrupt the process of viral replication which reduces the viral load but is much slower.
The fact that Brilacidin cleared 75% of the virus in one hour is confirms its potency. When combined with its long half life of several days after one IV dose it means it could be quite versatile and suggests a variety of different uses against Covid 19.
Brilacidin may prove effective as a single IV dose when people are first diagnosed, especially the elderly and chronically ill to prevent serious complications .It could be given to health care workers { or presidents} exposed to Covid19 after exposure to prevent infection.It could be combined with other antivirals which are virustatic to produce complementary results such as Remdesivir in patients with early pulmonary symptoms to protect against pulmonary failure.
IMO yesterdays PR means Brilacidin is almost certain to be in multilple clinical trials for a variety of indications in Covid19 infections.
Brilacidin is modeled after defensin proteins in terms of its polarity and biologic activity. Defensin proteins, like many proteins, are less stable.They are chains of amino acids which are held together with relatively weak chemical bonds. They are more likely to be damaged by digestive processes such as gastric acidity and intestinal processes. They have a shorter duration of action.They are expensive to produce and have been difficult to develop into pharmaceuticals even after decades of study.
Brilacidin is based on the chemical structure of a defensin, Magainin. Magainin was discovered by Michael Zasloff who attempted to develop it into an antibiotic. After several years he was frustrated in his research by the limitations outlined above.
Polymedix Researchers recognized these short comings and were able to replace the weaker peptide core with a more stable core consisting of stronger chemical aromatic rings and by using amides {arylamides} which allowed Brilacidin to be more stable but maintain its defensin like abilities. By biochemically altering the structure and using a supercomputer to predict how molecular changes in the alignment of its biologically active hyrophillic positive side with its negatively charge side they were able to increase its biologically activity many times over.
They studied scores of compounds this way and Brilacidin was unique in its abilities such as:
1.A strong antibiotic active against gram positive and some gram negative bacteria.
2.Immunomodulating characteristics to control the inflammatory efforts of the bodies immune system in a positive way.
3. The antiviral effects are currently being studied and to date have been initially positive with future studies to delineate its place as a treatment.
4. Multiple human studies have shown it to be safe.
5. Studies such as immune passage studies show it is less likely to develop bacterial resistance.
Dr Degrado and his team's goal was to mimic and improve the biologic actions of a a natural antibiotic in order to capture its biologic actions which have been honed by eons of evolution. Past studies have shown them to be successful; future studies may show researchers have only scratched the surface of its potential.
JMO
GLTA, Farrell
The fact that Brilacidin cleared 75% of the virus in one hour is confirms its potency. When combined with its long half life of several days after one IV dose it means it could be quite versatile and suggests a variety of different uses against Covid 19.
Brilacidin may prove effective as a single IV dose when people are first diagnosed, especially the elderly and chronically ill to prevent serious complications .It could be given to health care workers { or presidents} exposed to Covid19 after exposure to prevent infection.It could be combined with other antivirals which are virustatic to produce complementary results such as Remdesivir in patients with early pulmonary symptoms to protect against pulmonary failure.
IMO yesterdays PR means Brilacidin is almost certain to be in multilple clinical trials for a variety of indications in Covid19 infections.
Brilacidin is modeled after defensin proteins in terms of its polarity and biologic activity. Defensin proteins, like many proteins, are less stable.They are chains of amino acids which are held together with relatively weak chemical bonds. They are more likely to be damaged by digestive processes such as gastric acidity and intestinal processes. They have a shorter duration of action.They are expensive to produce and have been difficult to develop into pharmaceuticals even after decades of study.
Brilacidin is based on the chemical structure of a defensin, Magainin. Magainin was discovered by Michael Zasloff who attempted to develop it into an antibiotic. After several years he was frustrated in his research by the limitations outlined above.
Polymedix Researchers recognized these short comings and were able to replace the weaker peptide core with a more stable core consisting of stronger chemical aromatic rings and by using amides {arylamides} which allowed Brilacidin to be more stable but maintain its defensin like abilities. By biochemically altering the structure and using a supercomputer to predict how molecular changes in the alignment of its biologically active hyrophillic positive side with its negatively charge side they were able to increase its biologically activity many times over.
They studied scores of compounds this way and Brilacidin was unique in its abilities such as:
1.A strong antibiotic active against gram positive and some gram negative bacteria.
2.Immunomodulating characteristics to control the inflammatory efforts of the bodies immune system in a positive way.
3. The antiviral effects are currently being studied and to date have been initially positive with future studies to delineate its place as a treatment.
4. Multiple human studies have shown it to be safe.
5. Studies such as immune passage studies show it is less likely to develop bacterial resistance.
Dr Degrado and his team's goal was to mimic and improve the biologic actions of a a natural antibiotic in order to capture its biologic actions which have been honed by eons of evolution. Past studies have shown them to be successful; future studies may show researchers have only scratched the surface of its potential.
JMO
GLTA, Farrell
(15)
(0)